PT1117421E - Novos metodos para vacinacao terapeutica - Google Patents
Novos metodos para vacinacao terapeuticaInfo
- Publication number
- PT1117421E PT1117421E PT99945967T PT99945967T PT1117421E PT 1117421 E PT1117421 E PT 1117421E PT 99945967 T PT99945967 T PT 99945967T PT 99945967 T PT99945967 T PT 99945967T PT 1117421 E PT1117421 E PT 1117421E
- Authority
- PT
- Portugal
- Prior art keywords
- antigen
- weak
- analogues
- antigens
- immunogenic
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 238000002255 vaccination Methods 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 230000002163 immunogen Effects 0.000 abstract 3
- 101150029707 ERBB2 gene Proteins 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 229940124590 live attenuated vaccine Drugs 0.000 abstract 1
- 229940023012 live-attenuated vaccine Drugs 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA199801261 | 1998-10-05 | ||
US10501198P | 1998-10-20 | 1998-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1117421E true PT1117421E (pt) | 2004-11-30 |
Family
ID=26065489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT99945967T PT1117421E (pt) | 1998-10-05 | 1999-10-05 | Novos metodos para vacinacao terapeutica |
Country Status (25)
Country | Link |
---|---|
US (3) | US7005498B1 (pt) |
EP (1) | EP1117421B2 (pt) |
JP (1) | JP2002526419A (pt) |
KR (1) | KR100731820B1 (pt) |
CN (1) | CN1325115C (pt) |
AT (1) | ATE269100T1 (pt) |
AU (1) | AU751709B2 (pt) |
CA (1) | CA2345817C (pt) |
CZ (1) | CZ20011049A3 (pt) |
DE (1) | DE69918146T2 (pt) |
EA (1) | EA003634B1 (pt) |
EE (1) | EE200100203A (pt) |
ES (1) | ES2222728T3 (pt) |
HK (1) | HK1039749B (pt) |
HR (1) | HRP20010319A2 (pt) |
HU (1) | HUP0103976A3 (pt) |
IL (1) | IL141868A0 (pt) |
MX (1) | MXPA01003503A (pt) |
NO (1) | NO20011586L (pt) |
NZ (1) | NZ511055A (pt) |
PL (1) | PL202399B1 (pt) |
PT (1) | PT1117421E (pt) |
SK (1) | SK4272001A3 (pt) |
TR (1) | TR200100936T2 (pt) |
WO (1) | WO2000020027A2 (pt) |
Families Citing this family (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1072897A (en) | 1995-12-12 | 1997-07-03 | Karolinska Innovations Ab | Peptide binding the klvff-sequence of amyloid beta |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
HUP0103976A3 (en) | 1998-10-05 | 2008-04-28 | Pharmexa As | Novel methods for therapeutic vaccination |
US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
AU777952B2 (en) * | 1999-04-23 | 2004-11-04 | Pharmexa A/S | Method for down-regulating IL5 activity |
US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
BR0010322A (pt) * | 1999-05-06 | 2002-04-09 | Univ Wake Forest | Vetor de expressão, vacina e seu método de uso para eliciar uma resposta imune dirigida contra um antìgeno em um mamìfero |
BR0108566A (pt) * | 2000-02-21 | 2002-11-19 | Pharmexa As | Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico |
AU783144B2 (en) | 2000-02-21 | 2005-09-29 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
DE10042598A1 (de) * | 2000-08-30 | 2002-03-28 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS |
US8435939B2 (en) | 2000-09-05 | 2013-05-07 | Biokine Therapeutics Ltd. | Polypeptide anti-HIV agent containing the same |
JP2004508028A (ja) * | 2000-09-06 | 2004-03-18 | ファーメクサ エイ/エス | IgEをダウン−レギュレートさせる方法 |
WO2002034287A2 (en) * | 2000-10-27 | 2002-05-02 | Pharmexa A/S | Therapeutic vaccine formulations containing chitosan |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
AU2002233166B2 (en) * | 2001-02-19 | 2006-06-29 | Pharmexa A/S | Synthetic vaccines comprising polyhydroxypolymer carriers |
AU2002326751A1 (en) | 2001-08-13 | 2003-03-03 | Ige Therapeutics, Inc. | Immunoglobulin e vaccines and methods of use thereof |
MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
WO2003059379A2 (en) * | 2002-01-17 | 2003-07-24 | Pharmexa A/S | Immunogenic carcinoembryonic antigen (cea) |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1487477A4 (en) * | 2002-03-26 | 2006-07-19 | Immunex Corp | METHOD OF USE OF FLT3 LIGAND IN IMMUNIZATION PROTOCOLS |
EP1575500A4 (en) | 2002-07-12 | 2007-01-03 | Univ Johns Hopkins | MESOTHELIN VACCINE AND MODEL SYSTEMS |
US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
KR100555211B1 (ko) * | 2002-07-16 | 2006-03-03 | 주식회사 팬제노믹스 | 항암효과를 갖는 Her-2/neu DNA 백신 |
US7423007B2 (en) | 2002-08-27 | 2008-09-09 | Biokine Therapeutics Ltd. | Cxcr4 antagonist and use thereof |
GB0228796D0 (en) * | 2002-12-11 | 2003-01-15 | Adjuvantix Ltd | Valency |
SE0301109D0 (sv) * | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
JP2007535895A (ja) * | 2003-05-01 | 2007-12-13 | イムクローン システムズ インコーポレイティド | ヒトインシュリン様成長因子−1受容体に対する完全ヒト抗体 |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
CN101094864A (zh) | 2003-06-25 | 2007-12-26 | 法麦克萨有限公司 | Her-2变体的纯化 |
DK1641819T3 (da) | 2003-06-25 | 2009-08-03 | Bn Immunotherapeutics Inc | Oprensning af HER-2-varianter |
US20070014807A1 (en) * | 2003-09-03 | 2007-01-18 | Maida Anthony E Iii | Multiplex vaccine |
WO2005033278A2 (en) * | 2003-09-30 | 2005-04-14 | Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus iscom |
WO2005042575A2 (en) * | 2003-10-30 | 2005-05-12 | Pharmexa A/S | Method for down-regulation of vegf |
AU2003290460A1 (en) * | 2003-12-24 | 2005-07-14 | Leiden University Medical Center | Synthetic protein as tumor-specific vaccine |
US7674456B2 (en) * | 2004-06-14 | 2010-03-09 | Charles Wiseman | Breast cancer cell lines and uses thereof |
US20070190072A1 (en) * | 2004-09-30 | 2007-08-16 | Csl Limited Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
WO2006102901A2 (en) * | 2005-03-31 | 2006-10-05 | Pharmexa A/S | Immunogenic egfr peptides comprising foreign t cell stimulating epitope |
CN100354002C (zh) * | 2005-05-31 | 2007-12-12 | 中国人民解放军第三军医大学第一附属医院 | 一种新的以异种免疫细胞为细胞载体的细胞疫苗及其制备方法 |
EP2100614B8 (en) * | 2005-06-17 | 2013-11-20 | ImClone LLC | Antibody against PDGFR-alpha for use in the treatment of tumours |
EP2385060A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
EP1982176A1 (en) * | 2006-01-30 | 2008-10-22 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
EA017265B1 (ru) * | 2006-02-03 | 2012-11-30 | Имклоун Элэлси | Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы |
BRPI0707640A2 (pt) * | 2006-02-09 | 2011-05-10 | Transtech Pharma Inc | proteÍnas de fusço do rage e mÉtodos de uso |
EP2007435B1 (en) | 2006-03-31 | 2019-12-18 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
EA017291B1 (ru) * | 2006-05-05 | 2012-11-30 | Транстек Фарма, Инк. | Белки слияния на основе rage, их композиции и способы их применения |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
WO2007137586A2 (en) * | 2006-05-31 | 2007-12-06 | Pharmexa A/S | Random insertion of peptides |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
ES2500465T3 (es) * | 2006-10-06 | 2014-09-30 | Bavarian Nordic Inc. | Virus vaccinia Ankara modificado recombinante que codifica antígeno HER-2 en combinación con un taxano para uso en el tratamiento del cáncer |
ES2842210T3 (es) * | 2006-12-21 | 2021-07-13 | Biokine Therapeutics Ltd | 4F-benzoil-TN14003 para la movilización de células progenitoras hematopoyéticas con vistas al trasplante |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
US20090074828A1 (en) * | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2167537A2 (en) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Compiled methods for analysing and sorting samples |
DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
WO2009023266A1 (en) * | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members |
EP2853267B1 (en) * | 2007-09-21 | 2016-12-07 | The Regents of the University of California | Targeted interferon demonstrates potent apoptotic and anti-tumor activities |
US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
CN105770878A (zh) | 2007-10-12 | 2016-07-20 | 麻省理工学院 | 疫苗纳米技术 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
KR20160065985A (ko) * | 2007-10-18 | 2016-06-09 | 버베리안 노딕 에이/에스 | 전립선 암 치료를 위한 mva의 용도 |
DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
US10722562B2 (en) * | 2008-07-23 | 2020-07-28 | Immudex Aps | Combinatorial analysis and repair |
EP2367567A4 (en) * | 2008-08-05 | 2014-12-03 | Univ Queensland | SKELETONS HAVING ANTIGEN |
GB0817244D0 (en) * | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
US7998488B2 (en) | 2008-11-14 | 2011-08-16 | Baxter International Inc. | Vaccine formulations and uses thereof |
US9249187B2 (en) | 2009-01-28 | 2016-02-02 | Epimmune Inc. | Pan-DR binding polypeptides and uses thereof |
EP2413964B1 (en) | 2009-04-01 | 2019-11-13 | University of Miami | Vaccine compositions and methods of use thereof |
CA2762586C (en) * | 2009-05-19 | 2018-06-19 | University Of Miami | Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs |
KR101719339B1 (ko) | 2009-06-14 | 2017-03-23 | 바이오카인 테라퓨틱스 리미티드 | 혈소판 수준을 증가시키는 펩타이드 요법 |
CN102711791A (zh) | 2009-07-03 | 2012-10-03 | 比奥诺尔免疫有限公司 | 用于hiv疫苗组合物或作为诊断方法的hiv相关肽的组合或融合物 |
EA201592264A1 (ru) * | 2009-08-26 | 2016-08-31 | Селекта Байосайенсиз, Инк. | Композиции, которые индуцируют хелперное действие т-клеток |
KR20120093163A (ko) * | 2009-09-14 | 2012-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Il-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법 |
EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
CN103002915B (zh) * | 2010-04-13 | 2015-09-23 | 免疫创新治疗有限公司 | 抑制Treg细胞的方法和组合物 |
ES2661978T3 (es) | 2010-05-26 | 2018-04-04 | Selecta Biosciences, Inc. | Vacunas multivalentes de nanovehículos sintéticos |
EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
JP6077450B2 (ja) * | 2010-11-12 | 2017-02-08 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | コンセンサス前立腺抗原、それをコードする核酸分子、ならびにそれを含むワクチンおよび用途 |
EA034031B1 (ru) | 2011-01-06 | 2019-12-20 | Бионор Иммуно Ас | Димерный пептид для индуцирования иммунного ответа против hiv и его применение |
CN102716472A (zh) * | 2011-03-31 | 2012-10-10 | 李光辉 | 一种肿瘤疫苗及其合成方法 |
CN107261154A (zh) | 2011-04-29 | 2017-10-20 | 西莱克塔生物科技公司 | 致耐受性合成纳米载体 |
JP2014516538A (ja) * | 2011-05-26 | 2014-07-17 | ジーニウス バイオテクノロジー インベストメンツ リミテッド ライアビリティ カンパニー | 調節された免疫優勢療法 |
CN109172819A (zh) | 2011-07-29 | 2019-01-11 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体 |
EP3228321B1 (en) * | 2011-09-13 | 2019-04-10 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
CN103063836B (zh) * | 2011-10-18 | 2016-03-30 | 复旦大学附属华山医院 | 检测分枝杆菌感染的试剂、方法和试剂盒 |
CA2864841C (en) | 2012-02-17 | 2020-07-07 | Keith L. Knutson | Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
IN2014KN02774A (pt) | 2012-06-06 | 2015-05-08 | Bionor Immuno As | |
US10501499B2 (en) | 2012-06-06 | 2019-12-10 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
SG10201701866QA (en) | 2012-09-11 | 2017-04-27 | Oncotherapy Science Inc | Ube2t peptides and vaccines containing the same |
AU2013331328B2 (en) | 2012-10-19 | 2018-05-31 | Bavarian Nordic A/S | Methods and compositions for the treatment of cancer |
WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
WO2014100853A1 (en) * | 2012-12-28 | 2014-07-03 | Cellestis Limited | A cell mediated immune response assay |
WO2014194100A1 (en) | 2013-05-29 | 2014-12-04 | The Regents Of The University Of California | Anti-cspg4 fusions with interferon for the treatment of malignancy |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
US20170165321A1 (en) | 2014-07-11 | 2017-06-15 | Bionor Immuno As | Method for reducing and/or delaying pathological effects of human immunodeficiency virus i (hiv) or for reducing the risk of developing acquired immunodeficiency syndrome (aids) |
US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CA3016420A1 (en) * | 2015-03-11 | 2016-09-15 | Board Of Regents Of The University Of Nebraska | Conformationally stable analogs of the response selective c5a agonist ep67 |
EP3271455A4 (en) * | 2015-03-20 | 2018-08-08 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naive t cell population |
WO2016177833A1 (en) | 2015-05-04 | 2016-11-10 | Bionor Immuno As | Dosage regimen for hiv vaccine |
MA42420A (fr) | 2015-05-13 | 2018-05-23 | Agenus Inc | Vaccins pour le traitement et la prévention du cancer |
EP3744340A3 (en) | 2015-07-16 | 2021-03-03 | Biokine Therapeutics Ltd. | Compositions and methods for treating cancer |
PT3359183T (pt) * | 2015-10-06 | 2020-08-13 | Invectys | Construções de poliepítopo para utilização em imunoterapia |
AU2017222495B2 (en) | 2016-02-23 | 2019-08-08 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
CN105879058B (zh) * | 2016-05-10 | 2017-11-14 | 华中科技大学 | 一种结核病基因药物及其制备方法 |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
WO2019210055A2 (en) | 2018-04-26 | 2019-10-31 | Agenus Inc. | Heat shock protein-binding peptide compositions and methods of use thereof |
JP2022512595A (ja) | 2018-10-05 | 2022-02-07 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
CN111068069B (zh) * | 2018-10-18 | 2022-05-20 | 中国医学科学院药物研究所 | 一种免疫靶向功能性脂质体及其制备方法与用途 |
EP3883599A1 (en) | 2018-11-20 | 2021-09-29 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
EP4061406A1 (en) | 2019-11-20 | 2022-09-28 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
CN114096675A (zh) * | 2020-02-14 | 2022-02-25 | 艾天穆股份有限公司 | 冠状病毒免疫原性组合物和其用途 |
CN112980857A (zh) * | 2021-04-26 | 2021-06-18 | 重庆医科大学附属儿童医院 | 一种编码分泌性野生型gaa蛋白的核苷酸组合物、腺相关病毒载体及其药物和应用 |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
CA3240596A1 (en) | 2021-12-23 | 2023-06-29 | Cigdem ATAY LANGBEIN | Therapy for modulating immune response with recombinant mva encoding il-12 |
WO2024121411A1 (en) * | 2022-12-09 | 2024-06-13 | Strike Pharma Ab | Optimized tag moiety |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986007383A1 (en) | 1985-06-04 | 1986-12-18 | Biotechnology Research Partners, Ltd. | Autoantigen vaccines |
US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US5126399A (en) * | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
EP0420913B1 (en) * | 1988-06-14 | 1995-11-15 | Cell Med, Inc. | Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same |
CA2006700A1 (en) * | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
IT1237764B (it) * | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン,インコーポレイティド | 万能dr−結合性ペプチドを用いる免疫応答の改変 |
US5501063A (en) | 1994-09-06 | 1996-03-26 | Kimberly-Clark Corporation | Apparatus and method of reducing the force to expel a tampon from a tampon applicator and the applicator itself |
AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
US6410690B1 (en) * | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
AU721729B2 (en) | 1996-05-01 | 2000-07-13 | Avant Immunotherapeutics, Inc. | Plasmid-based vaccine for treating atherosclerosis |
CA2261990A1 (en) * | 1996-07-25 | 1998-02-05 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
AUPO390396A0 (en) * | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
WO1998025574A2 (en) * | 1996-12-10 | 1998-06-18 | Sloan-Kettering Institute For Cancer Research | Stimulation of an immune response to differentiation antigen stimulated by altered antigen |
AU724294B2 (en) | 1997-01-22 | 2000-09-14 | Eisai Inc. | Microparticles for delivery of nucleic acid |
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
WO1999040188A2 (en) | 1998-02-05 | 1999-08-12 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations |
WO1999056919A1 (de) | 1998-04-30 | 1999-11-11 | Manfred Schneider | Werkzeugmaschine mit werkzeugwechsel |
HUP0103976A3 (en) * | 1998-10-05 | 2008-04-28 | Pharmexa As | Novel methods for therapeutic vaccination |
-
1999
- 1999-10-05 HU HU0103976A patent/HUP0103976A3/hu unknown
- 1999-10-05 TR TR2001/00936T patent/TR200100936T2/xx unknown
- 1999-10-05 US US09/806,703 patent/US7005498B1/en not_active Expired - Lifetime
- 1999-10-05 SK SK427-2001A patent/SK4272001A3/sk unknown
- 1999-10-05 KR KR1020017004399A patent/KR100731820B1/ko not_active IP Right Cessation
- 1999-10-05 ES ES99945967T patent/ES2222728T3/es not_active Expired - Lifetime
- 1999-10-05 EP EP99945967.0A patent/EP1117421B2/en not_active Expired - Lifetime
- 1999-10-05 EA EA200100425A patent/EA003634B1/ru not_active IP Right Cessation
- 1999-10-05 CN CNB998117609A patent/CN1325115C/zh not_active Expired - Fee Related
- 1999-10-05 MX MXPA01003503A patent/MXPA01003503A/es not_active Application Discontinuation
- 1999-10-05 EE EEP200100203A patent/EE200100203A/xx unknown
- 1999-10-05 JP JP2000573386A patent/JP2002526419A/ja active Pending
- 1999-10-05 AT AT99945967T patent/ATE269100T1/de active
- 1999-10-05 PT PT99945967T patent/PT1117421E/pt unknown
- 1999-10-05 CZ CZ20011049A patent/CZ20011049A3/cs unknown
- 1999-10-05 AU AU58510/99A patent/AU751709B2/en not_active Expired
- 1999-10-05 PL PL347977A patent/PL202399B1/pl not_active IP Right Cessation
- 1999-10-05 WO PCT/DK1999/000525 patent/WO2000020027A2/en not_active Application Discontinuation
- 1999-10-05 NZ NZ511055A patent/NZ511055A/en not_active IP Right Cessation
- 1999-10-05 DE DE69918146T patent/DE69918146T2/de not_active Expired - Lifetime
- 1999-10-05 CA CA2345817A patent/CA2345817C/en not_active Expired - Lifetime
- 1999-10-05 IL IL14186899A patent/IL141868A0/xx not_active IP Right Cessation
-
2001
- 2001-03-28 NO NO20011586A patent/NO20011586L/no not_active Application Discontinuation
- 2001-05-04 HR HR20010319A patent/HRP20010319A2/hr not_active Application Discontinuation
-
2002
- 2002-02-09 HK HK02101047.9A patent/HK1039749B/zh not_active IP Right Cessation
-
2003
- 2003-05-19 US US10/441,779 patent/US7820633B2/en not_active Expired - Fee Related
-
2005
- 2005-08-11 US US11/202,516 patent/US7807441B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1117421E (pt) | Novos metodos para vacinacao terapeutica | |
BR9306984A (pt) | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo | |
ME00183B (me) | Novi postupak za deregulaciju amiloida | |
IL150602A (en) | Proteosome influenza vaccine, method for preparing such and use thereof | |
BRPI9912177B8 (pt) | epítopos de célula auxiliar t artificiais como imunoestimuladores para imunógenos de peptídeo sintéticos, imunógenos de peptídeo e método para a produção dos mesmos | |
EE200200507A (et) | Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine | |
EP0794797A4 (en) | METHODS AND EQUIPMENT FOR IMMUNIZING A HOST BY ADMINISTERING NAKED POLYNUCLEOTIDES ENCODING ANTIGEN PEPTIDES | |
DE69929444D1 (de) | Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung | |
ATE411043T1 (de) | Verfahren von dna-impfung | |
TR200400621T2 (tr) | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. | |
HK1093314A1 (en) | Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens | |
DE60325696D1 (de) | Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs | |
DK0880360T3 (da) | Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop | |
BR0111834A (pt) | Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno | |
ATE103297T1 (de) | Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea. | |
JP2002534481A5 (pt) | ||
FI924222A (fi) | Gp75 som ett tumoervaccin mot melanoma | |
WO2003059379A3 (en) | Immunogenic carcinoembryonic antigen (cea) | |
SE9903534D0 (sv) | Vaccin | |
EP1502602A3 (en) | Methods for therapeutic vaccination | |
BR9709993A (pt) | Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica | |
YU24401A (sh) | Novi postupci za terapeutsku vakcinaciju | |
TNSN08184A1 (en) | Chimeric antigens and vaccines | |
DK1146889T3 (da) | Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407 | |
BR0009746A (pt) | Molécula de veìculo, composição imunogênica, polipeptìdeo, método para tratar um indivìduo, e, plasmìdeos pebl1-pv e pviii |